Prevention, early diagnosis, and effective treatment are essential for the control and elimination of Neisseria gonorrhoeae as a public health problem. Currently, in Latin America and the Caribbean, treatment for gonorrhea infection is largely empiric and based on clinical diagnosis. In the Americas, the high burden of new N. gonorrhoeae infections (estimated at 11 million new cases a year), the complexity of the disease epidemiology, and in many countries the limited resources, make it difficult to fully understand the burden of disease and the burden of antimicrobial resistance (AMR) in N. gonorrhoeae. PAHO has developed this document to facilitate the navigation of available guidance and recommendations for N. gonorrhoeae AMR surveillance by public health and health care professionals, at the national and subnational levels, involved in designing, implementing, and/or strengthening AMR surveillance of N. gonorrhoeae and overall surveillance of sexually transmitted infections

The consolidated guidelines are complemented by an operational handbook which is designed to assist with implementation of the WHO recommendations by Member States, technical partners and others who are involved in the management of patients with DR-TB. The WHO Operational Handbook on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment provides practical guidance on how to put in place the recommendations at the scale needed to achieve national and global impact. The operational handbook provides practical information and tools that complement the recommendations in the guidelines. The strategies described in the operational handbook are based on the latest WHO recommendations which were formulated by Guideline Development Groups using the GRADE approach. In many cases however, the recommendations in their current form lacked sufficient clinical and programmatic detail, which is important for implementation. This operational handbook complements the guidelines with practical advice based on best practices and knowledge from the fields such as pharmacokinetics, pharmacodynamics, microbiology, pharmacovigilance and clinical and programmatic management

This training toolkit by the European Laboratory Initiative for TB, HIV and Viral Hepatitis provides a unique combination of practical guidance and expert advice on the interpretation of selected WHO-endorsed tests for drug-resistant tuberculosis (DR-TB)

Accessed on 28.02.2020

Developed by the HHS Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission— A Working Group of the Office of AIDS Research Advisory Council (OARAC) Accessed: 12.02.202

Las infecciones de transmisión sexual (ITS) constituyen un importante problema de salud pública en todo el mundo, que afecta a la calidad de vida y se acompaña de importantes niveles de morbilidad y mortalidad. Estas infecciones influyen directamente en la salud infantil y reproductiva porque traen consigo infertilidad, cánceres y complicaciones del embarazo. También tienen una influencia indirecta porque facilitan la transmisión por vía sexual del virus de la inmunodeficiencia humana (VIH), pesando así igualmente en la economía de los países y las personas. Cada día, más de un millón de personas contraen una infección de transmisión sexual. Se calcula que en 2012 hubo en el mundo 357 millones de nuevos casos de ITS curables (blenorragia, clamidiasis, sífilis o tricomoniasis) que afectaron a adultos de entre 15 y 49 años de edad, entre ellos 5,6 millones de casos de sífilis. El número de casos prevalentes de sífilis asciende, según las estimaciones, a unos 18 millones

The World malaria report 2019 provides a comprehensive update on global and regional malaria data and trends. The report tracks investments in malaria programmes and research as well as progress across all intervention areas: prevention, diagnosis, treatment, elimination and surveillance. It also includes dedicated chapters on the consequences of malaria on maternal, infant and child health, the “High Burden to High Impact” approach as well as biological threats to the fight against malaria. The 2019 report is based on information received from more than 80 countries and areas with ongoing malaria transmission. This information is supplemented by data from national household surveys and databases held by other organizations

Policy brief. These consolidated guidelines bring together existing and new evidence-based guidance and recommendations for delivering high-impact HIV testing services, including linkage to HIV prevention and treatment, in diverse settings and populations. A key objective of these guidelines is to encourage greater national and global commitment to implementing effective and efficient HTS as a vital element of the national and global HIV response, essential to achieving and maintaining low HIV incidence

Provide guidance to HIV care practitioners on the optimal use of antiretroviral (ARV) agents for the treatment of HIV infection in adults and adolescents.

Version 10.0 October 2019 These Guidelines are available in different formats: As a paper booklet, a PDF, a mobile app, and now also as a website. The 2019 version of the Guidelines introduces a new drug-drug interaction panel and now consists of six main sections, including a general overview table of all major issues in PLWH, recommendations on antiretroviral treatment, drug-drug interactions, diagnosis, monitoring and treatment of co-morbidities, co-infections and opportunistic diseases. Available in English, French, Spanish, German, Portuguese, Russian, Chinese and Japanes